Pulse Checks

Zitter Pulse Check: Acute Myeloid Leukemia (September 2022)

Acute myeloid leukemia (AML) is a high-cost category with an increasing number of therapies that treat different subtypes of the condition. To help stakeholders absorb datapoints and perceptions from all directions and synthesize those insights into a tangible strategy for AML, Zitter Insights surveys a leading panel of pharmacy and therapeutics (P&T) decision makers at payers and integrated delivery networks. The Managed Care Oncology Index: Acute Myeloid Leukemia combines deep payer insights with the industry standard in market access information to produce quarterly reports and insights summaries on leading oncology brands.

0 Comments

Zitter Pulse Check: Severe Asthma (September 2022)

Severe asthma is a high-cost category with an increasing number of therapies that treat the condition. To help stakeholders absorb datapoints and perceptions from all directions and synthesize those insights into a tangible strategy for severe asthma, Zitter Insights surveys a leading panel of pharmacy and therapeutics (P&T) decision makers at payers and integrated delivery networks. The Managed Care Biologics and Injectables Index combines deep payer insights with the industry standard in market access information to produce quarterly reports and insights summaries on leading specialty brands.

0 Comments

Zitter Pulse Check: Diabetes (August 2022)

Diabetes is a high-cost category with an increasing number of therapies that treat the condition. To help stakeholders absorb datapoints and perceptions from all directions and synthesize those insights into a tangible strategy for diabetes, Zitter Insights surveys a leading panel of pharmacy and therapeutics (P&T) decision makers at payers and integrated delivery networks. The Managed Care Biologics and Injectables Index combines deep payer insights with the industry standard in market access information to produce quarterly reports and insights summaries on leading specialty brands.

0 Comments

Zitter Pulse Check: Atopic Dermatitis (August 2022)

Atopic dermatitis is a high-cost category with an increasing number of therapies that treat the condition. To help stakeholders absorb datapoints and perceptions from all directions and synthesize those insights into a tangible strategy for atopic dermatitis, Zitter Insights surveys a leading panel of pharmacy and therapeutics (P&T) decision makers at payers and integrated delivery networks. The Managed Care Biologics and Injectables Index combines deep payer insights with the industry standard in market access information to produce quarterly reports and insights summaries on leading specialty brands.

0 Comments

Zitter Pulse Check: Psoriasis (August 2022)

Psoriasis is a high-cost category with an increasing number of therapies that treat the condition. To help stakeholders absorb datapoints and perceptions from all directions and synthesize those insights into a tangible strategy for psoriasis, Zitter Insights surveys a leading panel of pharmacy and therapeutics (P&T) decision makers at payers and integrated delivery networks. The Managed Care Biologics and Injectables Index combines deep payer insights with the industry standard in market access information to produce quarterly reports and insights summaries on leading specialty brands.

0 Comments

Zitter Pulse Check: Metastatic Melanoma (June 2022)

Coverage Metastatic melanoma is a high-cost category with an increasing number of therapies that treat the condition. To help stakeholders absorb datapoints and perceptions from all directions and synthesize those ...
0 Comments

Zitter Pulse Check: Non-Small Cell Lung Cancer (June 2022)

Coverage Non-small cell lung cancer (NSCLC) is a high-cost category with an increasing number of therapies that treat different subtypes of the condition. To help stakeholders absorb datapoints and perceptions from...
0 Comments

Zitter Pulse Check: Breast Cancer (June 2022)

Coverage Breast cancer is a high-cost category with an increasing number of therapies, including biosimilars, that treat different subtypes of the condition. To help stakeholders absorb datapoints and perceptions f...
0 Comments

Zitter Pulse Check: Orphan Drugs/Spinal Muscular Atrophy (June 2022)

Coverage Orphan drugs is a high-cost category with an increasing number of therapies that treat the conditions. To help stakeholders absorb datapoints and perceptions from all directions and synthesize those insigh...
0 Comments

Zitter Pulse Check: Rheumatoid Arthritis (May 2022)

Coverage Rheumatoid arthritis (RA) is a high-cost category with an increasing number of therapies that treat the condition. To help stakeholders absorb datapoints and perceptions from all directions and synthesize ...
0 Comments